RE:RE:Another solid quarterHere's some background on the work at McMaster for fibrosis;
https://macsphere.mcmaster.ca/handle/11375/27162 [url=https://healthsci.mcmaster.ca/home/2021/11/11/mcmaster's-research-team-discovers-new-mechanism-to-reprogram-macrophages-for-potential-fibrotic-disease-and-covid-19-therapiy]https://healthsci.mcmaster.ca/home/2021/11/11/mcmaster's-research-team-discovers-new-mechanism-to-reprogram-macrophages-for-potential-fibrotic-disease-and-covid-19-therapiy[/url]
and the recent NR on overall collaborative work has expanded therapeutic to prophylactic (preventative) as well.
https://www.ceapro.com/news/press-releases/detail/233/ceapro-inc-expands-collaborative-research-program-with prophetoffactz wrote: "Results from animal studies are being analyzed as part of a PhD thesis."
During the recent interview Gilles wanted to get something out this summer. No timeline in todays news release. The bioavailability data is expected next month. Health Canada was on a 90 day clock for approval of the avenanthramide trial and today's news release anticipates approval in Q4.